Inhibitory effect of dehydroabietylamine-fluorobenzaldehyde on human hepatocellular carcinoma cells

Chinese Pharmaceutical Journal

Volumn 48, Issue 4, 2013, Pages 269-274

  Liu, Ling ^a   Li, Fu ^b   He, Ling ^b   Rao, Xiao Ping ^b   Song, Zhan Qian ^b  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Pharmaceutical University   (China)

Author keywords

1 (7 isopropyl 1, 4a dimethyl 1, 2, 3, 4, 4a, 9, 10, 10a octahydrophenanthren l yl) N (4 fluorobenzylidene) methanamine; Apoptosis; Dehydroabietylamine fluorobenzaldehyde; Hepatocellular carcinoma; Mitochondria

Indexed keywords

ANTINEOPLASTIC AGENT; BENZALDEHYDE DERIVATIVE; CASPASE 3; CELL PROTEIN; CYT C PROTEIN; DEHYDROABIETYL AMINE FLUOROBENZALDEHYDE[1 (7 ISOPROPYL 1, 4A DIMETHYL 1, 2, 3, 4, 4A, 9, 10, 10A OCTAHYDROPHENANTHREN L YL) N (4 FLUOROBENZYLI DENE) METHANAMINE; DEHYDROABIETYLAMINE FLUOROBENZALDEHYDE; DHAA F; METHYLAMINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CYTOSOL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PROTEIN EXPRESSION; SPECTROFLUOROMETRY; TUMOR WEIGHT; WESTERN BLOTTING;

EID: 84889005390     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: 10.11669/cpj.2013.04.007     Document Type: Article

References (12)

1. YANG J D, ROBERTS L R. Hepatocellular carcinoma: A global view[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8): 448-458.
2. HUANG C U, HUANG K U, WU R, et al. Performance and application of dehydroabietylamine[J]. Technol Develop Chem hid, 2010, 39(2): 21-25.
3. RAO X P, SONG ZH Q, GAO H. Research and application progress on dehydroabietylamine and its derivatives[J]. Chemistry, 2006, 69(3): 168-172.
4. XIE J X, HE U, ZHANG U Y. Inhibition of glucometabolism by a novel dehydroabielylamine derivative, DHAA-urea, in human hepatoma HepG2 cells[J]. J China Pharm Univ, 2010, 41(2): 160-165.
5. RAO X P, SONG Z Q, GAO H. Synthesis and antibacterial activity of fluorine-containing Schiff bases derived from dehydroabietylamine[J]. Chem Ind Forest Prod, 2007, 27(2): 97-99.
6. ORRENIUS S. Mitochondrial regulation of apoptotic cell death[J]. Toxicol Lett, 2004, 149(1-3): 19-23.
7. CHEUNG J Y, ONG R C, SUEN Y K, el al. Polyphyllin D is a potent apoptosis inducer in drug-resistant HepG2 cells[J]. Cancer Lett, 2005, 217(2): 203-211.
8. GARTEU A L. Mechanisms of apoptosis induced by anticancer compounds in melanoma cells[J]. Curr Top Med Chem, 2012, 12(1): 50-52.
9. NORBERG E, ORRENIUS S, ZHIVOTOVSKY B. Mitochondrial regulation of cell death: Processing of apoptosis-inducing factor (AIF)[J]. Biochem Biophys Res Commun, 2010, 396(1): 95-100.
10. HAN U U, XIE L P, LI U H, et al. Reactive oxygen species production and Bax/Bcl-2 regulation in honokiol-induced apoptosis in human hepatocellular carcinoma SMMC-7721 cells[J]. Environ Toxicol Pharmacol, 2009, 28(1): 97-103.
11. HuITEMANN M, PECINA P, RAINBOUT M, et al. The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis[J]. Mitochondrion, 2011, 11(3): 369-381.
12. ZHAO J, LU Y, SHEN H M. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells[J]. Cancer Lett, 2012, 314(1): 8-23.